Journal: BMJ Open

Article Title: Citalopram for major depressive disorder in adults: a systematic review and meta-analysis of published placebo-controlled trials

doi: 10.1136/bmjopen-2011-000106

Figure Lengend Snippet: Random effects meta-analysis of symptom responses for citalopram and placebo.

Article Snippet: A meta-analysis of response rates was performed to calculate an overall RR of a response to citalopram, compared with placebo, in a random-effects model, using Stata V.9.2.

Techniques:

Journal: BMJ Open

Article Title: Citalopram for major depressive disorder in adults: a systematic review and meta-analysis of published placebo-controlled trials

doi: 10.1136/bmjopen-2011-000106

Figure Lengend Snippet: Funnel plot of symptom response odds ratios for citalopram and placebo.

Article Snippet: A meta-analysis of response rates was performed to calculate an overall RR of a response to citalopram, compared with placebo, in a random-effects model, using Stata V.9.2.

Techniques:

Journal: BMJ Open

Article Title: Citalopram for major depressive disorder in adults: a systematic review and meta-analysis of published placebo-controlled trials

doi: 10.1136/bmjopen-2011-000106

Figure Lengend Snippet: Meta-analysis of standardised mean differences (SMD) in change from baseline HAM-D comparing citalopram and placebo.

Article Snippet: A meta-analysis of response rates was performed to calculate an overall RR of a response to citalopram, compared with placebo, in a random-effects model, using Stata V.9.2.

Techniques:

Journal: JAMA

Article Title: Automated surveillance to detect post-procedure safety signals of approved medical devices

doi: 10.1001/jama.2010.1633

Figure Lengend Snippet: Medical devices analyzed, outcomes captured, control populations and final alert status for each analysis

Article Snippet: The FilterWire ® embolic protection device and the Angio-Seal STS ® device required expansion of control patient populations due to very high utilization rates (and therefore limited concurrent controls in same device group) of the devices of interest. table ft1 table-wrap mode="anchored" t5 caption a7 Device Monitored Mini-Vision BMS (Guidant/Abbott) Taxus-Express DES (Boston Scientific) a Cypher DES (Cordis) b FilterWire EPD (Boston Scientific) c Angio-Seal STS VCD (St. Jude Medical) d StarClose VCD (Abbott) Perclose Proglide VCD (Abbott) Surveillance Dates Jan 2005 - Dec 2007 April 2004 - Dec 2007 April 2004 - Dec 2007 Nov 2005 - Dec 2007 Jan 2005 - Dec 2007 Apr 2006 - Dec 2007 Jan 2005 - Dec 2007 Total Device Exposures 3 253 18 277 28 955 892 10 801 2 291 2 171 Number of Quarterly Analyses 11 15 15 11 11 7 11 Average Quarterly Exposure 295 1 218 1930 81 980 327 197 Standard Deviation of Mean Average Quarterly Exposure 158.9 463.1 544.3 22.2 267.1 41.1 62.7 Comparator Group Alternative BMS with diameter <2.75mm Alternative DES (predominately Cypher) Alternative DES (predominately Taxus) PCI procedures on SVG without EPD use Alternative VCD or mechanical hemostasis Alternative VCD or mechanical hemostasis Alternative VCD or mechanical hemostasis Cases Matched 1 959 14 893 14 743 599 8 015 2 277 2 160 Match Proportion 55.6% 81.5% 50.9% 67.1% 74.2% 99.4% 99.5% Outcomes Monitored In hospital death, post-procedure MI, MACE In hospital death, post-procedure MI, MACE In hospital death, post-procedure MI, MACE In hospital death, post-procedure MI, MACE Major, Minor and Any Vascular Complication Major, Minor and Any Vascular Complication Major, Minor and Any Vascular Complication Safety Alerts Triggered none Post-procedure MI, MACE none none Major Vascular Complication none none Time to First Safety Alert 15 months (6 764 cases) 12 months (3 287 cases) Open in a separate window Abbreviations: BMS, bare metal stent; DES, Drug Eluting Stent; SVG, saphenous vein graft a A small number of alternative DES used as part of clinical trials included in match b Device approved April, 2003; Insufficent comparators until April 2004 c Insufficient comparator EPD devices available in dataset d Improved outcomes over time associated with changes in anticoagulation strategy caption a8 Medical devices analyzed, outcomes captured, control populations and final alert status for each analysis Of the 21 safety analyses performed, three (14%) generated a repeated or sustained safety signal involving two implanted devices, prompting detailed sensitivity analysis per study protocol ( ).

Techniques: Standard Deviation